Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

J&J in the Hunt for China M&A

publication date: Sep 17, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Johnson & Johnson is using “external innovation” in China as a low-cost, highly inventive path to discover new drugs. "We have to seek the best science and technology,” said Lily Lee, PhD, vice-president and head of JNJ Pharmaceutical R&D Asia, at a recent Shanghai biopharma meeting. "We are especially interested in oncology, infectious diseases and metabolic areas, so M&As in these areas will be high on our radar screen," she continued. More details....

Stock Symbol: (NYSE: JNJ)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...